Navigation Links
ReShape Medical Announces Initiation of U.S. Clinical Study for Weight Loss
Date:3/3/2010

SAN CLEMENTE, Calif., March 3 /PRNewswire/ -- ReShape Medical™, Inc. announced today that it has initiated a U.S. Investigational Device Exemption (IDE) clinical study to assess the safety and effectiveness of its non-surgical, dual-balloon device for weight loss.  The ReShape Balloons are designed to be a treatment for the millions who want support with weight loss, without the invasiveness of surgery. The ReShape device occupies existing space in the stomach to reduce its capacity for food.  The balloons remain in place for six-months and are then removed.

The first U.S. study participant received the ReShape Balloons Treatment at The N.E.W. Program in Newport Beach, Calif., under the care of Brian Quebbemann, M.D., FACS, and Surgical Director of The N.E.W. Program.  "At 6'2" and 263 pounds, this 31-year old man did not qualify for bariatric surgery, and had exhausted his efforts with diets that didn't work," said Dr. Quebbemann.  

Dr. Quebbemann added, "Countless Americans have grown beyond a healthy weight and struggle with conventional methods of weight loss, but can't or won't undergo surgery.  This group is ideally suited for a non-surgical weight loss treatment such as the ReShape device being evaluated in this study."

"We are very pleased to initiate the U.S. IDE clinical study to evaluate the safety and efficacy of this emerging weight loss treatment.  There are millions of Americans who have a BMI over 30, but there are few options available to help them with their weight loss," said Bill Murray, President and CEO of ReShape Medical, Inc.  "We are pioneering the next-generation weight loss solution."

About ReShape Medical, Inc.

ReShape Medical is a development-stage medical device manufacturer headquartered in Southern California. The company is focused on the development of a non-surgical weight loss device that can be used as an aid in the treatment of obese or overweight patients.  

CAUTION--Investigational device.  Limited by United States law to investigational use.

For more information, please visit www.reshapemedical.com.  

SOURCE ReShape Medical, Inc.

Back to top

RELATED LINKS
http://www.reshapemedical.com

'/>"/>

SOURCE ReShape Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. As Biopharma Companies Reshape Sales Model, Most See Resetting Territory Size and Implementing Individualized Call Plans as First Steps Toward Change, According to New Research From Best Practices, LLC
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Globus Medical Raises $110 Million in Series E Financing Round
6. Quark Pharmaceuticals Appoints New Chief Medical Officer
7. Boston University Biomedical Engineers Find Chink in Bacterias Armor
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets ... Pipeline and Market Prospects: Addressing Production Complexities Through Risk ... offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities ... in-depth assessment of the current trends in the global ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., a ... drug prescribing process, today announced it closed $25 million in ... venture capital firm based in Seattle ... Venture Partners . The Series B round included participation from ... in 2014, and GV (formerly Google Ventures). As ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to popular ... violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and his ... in violence in the United States. The study, Trends in Fighting and ...
(Date:4/21/2017)... PA (PRWEB) , ... April 21, 2017 , ... Dudnyk ... new identity emphasizes the agency’s conviction that the full potential of specialty and orphan ... are equally appreciated and aligned. , “The Unifying Effect is at the heart ...
(Date:4/21/2017)... ... 21, 2017 , ... Crossover Symmetry , an evidence ... active lifestyle company that provides Human Performance Training and education to tactical athletes. ... responders, military officers and others in service through the development and conditioning of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... world leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl ... to work because the plan is given by the Creator Himself. , Yisrayl says ...
Breaking Medicine News(10 mins):